Keros Therapeutics, Inc. $KROS Stock Position Lifted by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd grew its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 40.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 164,483 shares of the company’s stock after acquiring an additional 47,122 shares during the quarter. Y Intercept Hong Kong Ltd owned approximately 0.83% of Keros Therapeutics worth $1,816,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in KROS. The Manufacturers Life Insurance Company lifted its stake in Keros Therapeutics by 8.6% during the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after purchasing an additional 988 shares during the last quarter. UBS Group AG increased its stake in Keros Therapeutics by 1.1% during the third quarter. UBS Group AG now owns 103,864 shares of the company’s stock valued at $1,643,000 after purchasing an additional 1,091 shares during the last quarter. Strs Ohio increased its stake in Keros Therapeutics by 3.9% during the fourth quarter. Strs Ohio now owns 29,300 shares of the company’s stock valued at $597,000 after purchasing an additional 1,100 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after purchasing an additional 1,166 shares during the period. Finally, Financial Management Professionals Inc. acquired a new stake in shares of Keros Therapeutics during the fourth quarter worth $29,000. 71.56% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

KROS has been the subject of several research reports. Wall Street Zen lowered shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings lowered shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Keros Therapeutics presently has an average rating of “Hold” and a consensus price target of $20.40.

Insiders Place Their Bets

In other news, Director Julius Knowles sold 2,625 shares of Keros Therapeutics stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the transaction, the director directly owned 10,958 shares in the company, valued at approximately $117,579.34. This trade represents a 19.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the sale, the director directly owned 9,767 shares in the company, valued at $104,799.91. This represents a 21.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,425 shares of company stock worth $89,994 over the last ninety days. Company insiders own 20.60% of the company’s stock.

Keros Therapeutics Trading Up 3.1%

KROS stock opened at $12.03 on Friday. Keros Therapeutics, Inc. has a 52 week low of $9.69 and a 52 week high of $22.55. The company has a market capitalization of $238.07 million, a price-to-earnings ratio of -4.00 and a beta of 0.97. The firm’s 50-day moving average is $10.95 and its two-hundred day moving average is $13.72.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The company had revenue of $0.37 million during the quarter, compared to analyst estimates of $1.93 million. On average, equities research analysts predict that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.